抗体–药物偶联物在宫颈癌治疗中的进展
Progress of Antibody-Drug Conjugates in the Treatment of Cervical Cancer
DOI: 10.12677/jcpm.2024.34334, PDF,   
作者: 李凯芳, 黄彬婷, 张富亿, 巫祥生, 李也鹏*：右江民族医学院研究生学院，广西 百色
关键词: 抗体–药物偶联物；宫颈癌；靶点；Antibody-Drug Conjugate； Cervical Cancer； Target
摘要: 宫颈癌是全球女性健康领域面临的一项重大挑战，当下迫切需要全新的治疗策略。抗体药物偶联物(ADC)作为一种新型治疗手段，通过将细胞毒性药物精确递送至肿瘤细胞，为宫颈癌治疗提供了新的治疗方向。本综述旨在探讨ADC在宫颈癌治疗中的应用，包括其作用机制、结构设计、临床研究进展及当前面临的挑战。我们详细分析了针对特定靶点如组织因子(TF)、人表皮生长因子受体2 (HER2)、Trop-2等的ADC，并评估了它们在宫颈癌治疗中的潜在价值与局限性。尽管抗体–药物偶联物在提升宫颈癌治疗效果以及减少副作用方面呈现出优势，但仍需攻克其耐药性、毒性管理等难题。未来的研究应当致力于开发新的靶点、优化ADC设计，同时开展更多的临床试验，以促使ADC在宫颈癌治疗中得到广泛应用。
Abstract: Cervical cancer is a major challenge in the field of global women’s health, and a new treatment strategy is urgently needed. Antibody drug conjugate (ADC), as a new treatment method, provides a new therapeutic direction for the treatment of cervical cancer by accurately delivering cytotoxic drugs to tumor cells. This review aims to explore the application of ADC in the treatment of cervical cancer, including its mechanism of action, structural design, clinical research progress and current challenges. We analyzed ADCs targeting specific targets such as tissue factor (TF), human epidermal growth factor receptor 2 (HER2), and Trop-2 in detail, and evaluated their potential value and limitations in the treatment of cervical cancer. Although antibody-drug conjugates have shown advantages in improving the therapeutic effect of cervical cancer and reducing side effects, they still need to overcome problems such as drug resistance and toxicity management. Future research should focus on developing new targets, optimizing ADC design, and conducting more clinical trials to promote the wide application of ADC in the treatment of cervical cancer.
文章引用：李凯芳, 黄彬婷, 张富亿, 巫祥生, 李也鹏. 抗体–药物偶联物在宫颈癌治疗中的进展[J]. 临床个性化医学, 2024, 3(4): 2337-2347. https://doi.org/10.12677/jcpm.2024.34334

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Olusola, P., Banerjee, H.N., Philley, J.V. and Dasgupta, S. (2019) Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. Cells, 8, Article No. 622. [Google Scholar] [CrossRef] [PubMed]
[3] Joubert, N., Beck, A., Dumontet, C. and Denevault-Sabourin, C. (2020) Antibody-drug Conjugates: The Last Decade. Pharmaceuticals, 13, Article No. 245. [Google Scholar] [CrossRef] [PubMed]
[4] Gennigens, C., Jerusalem, G., Lapaille, L., De Cuypere, M., Streel, S., Kridelka, F., et al. (2022) Recurrent or Primary Metastatic Cervical Cancer: Current and Future Treatments. ESMO Open, 7, Article ID: 100579. [Google Scholar] [CrossRef] [PubMed]
[5] 张巧云. Oba01对吉非替尼耐药NSCLC细胞的杀伤作用[D]: [硕士学位论文]. 咸宁: 湖北科技学院, 2023.
[6] Strebhardt, K. and Ullrich, A. (2008) Paul Ehrlich’s Magic Bullet Concept: 100 Years of Progress. Nature Reviews Cancer, 8, 473-480. [Google Scholar] [CrossRef] [PubMed]
[7] Hasan, M., Alam, S. and Poddar, S.K. (2019) Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti-Cancer Therapy. Current Clinical Pharmacology, 13, 236-251. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, S. (2015) Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Pharmaceutical Research, 32, 3577-3583. [Google Scholar] [CrossRef] [PubMed]
[9] Staudacher, A.H. and Brown, M.P. (2017) Antibody Drug Conjugates and Bystander Killing: Is Antigen-Dependent Internalisation Required? British Journal of Cancer, 117, 1736-1742. [Google Scholar] [CrossRef] [PubMed]
[10] Junutula, J.R., Bhakta, S., Raab, H., Ervin, K.E., Eigenbrot, C., Vandlen, R., et al. (2008) Rapid Identification of Reactive Cysteine Residues for Site-Specific Labeling of Antibody-Fabs. Journal of Immunological Methods, 332, 41-52. [Google Scholar] [CrossRef] [PubMed]
[11] Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., et al. (2008) Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index. Nature Biotechnology, 26, 925-932. [Google Scholar] [CrossRef] [PubMed]
[12] Rabuka, D., Rush, J.S., deHart, G.W., Wu, P. and Bertozzi, C.R. (2012) Site-Specific Chemical Protein Conjugation Using Genetically Encoded Aldehyde Tags. Nature Protocols, 7, 1052-1067. [Google Scholar] [CrossRef] [PubMed]
[13] Sunbul, M. and Yin, J. (2009) Site Specific Protein Labeling by Enzymatic Posttranslational Modification. Organic & Biomolecular Chemistry, 7, Article No. 3361. [Google Scholar] [CrossRef] [PubMed]
[14] Gauzy-Lazo, L., Sassoon, I. and Brun, M. (2020) Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations. SLAS Discovery, 25, 843-868. [Google Scholar] [CrossRef] [PubMed]
[15] Kondrashov, A., Sapkota, S., Sharma, A., Riano, I., Kurzrock, R. and Adashek, J.J. (2023) Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload. Pharmaceutics, 15, Article No. 2160. [Google Scholar] [CrossRef] [PubMed]
[16] Tiller, K.E. and Tessier, P.M. (2015) Advances in Antibody Design. Annual Review of Biomedical Engineering, 17, 191-216. [Google Scholar] [CrossRef] [PubMed]
[17] Beck, A., Goetsch, L., Dumontet, C. and Corvaïa, N. (2017) Strategies and Challenges for the Next Generation of Antibody-drug Conjugates. Nature Reviews Drug Discovery, 16, 315-337. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, H., Lin, Z., Arnst, K., Miller, D. and Li, W. (2017) Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules, 22, Article No. 1281. [Google Scholar] [CrossRef] [PubMed]
[19] Pahl, A., Lutz, C. and Hechler, T. (2018) Amanitins and Their Development as a Payload for Antibody-Drug Conjugates. Drug Discovery Today: Technologies, 30, 85-89. [Google Scholar] [CrossRef] [PubMed]
[20] Drago, J.Z., Modi, S. and Chandarlapaty, S. (2021) Unlocking the Potential of Antibody-Drug Conjugates for Cancer Therapy. Nature Reviews Clinical Oncology, 18, 327-344. [Google Scholar] [CrossRef] [PubMed]
[21] Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. (2022) Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy. Signal Transduction and Targeted Therapy, 7, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[22] Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M.C., Lenox, J., Cerveny, C.G., et al. (2004) Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate. Clinical Cancer Research, 10, 7063-7070. [Google Scholar] [CrossRef] [PubMed]
[23] Jain, N., Smith, S.W., Ghone, S. and Tomczuk, B. (2015) Current ADC Linker Chemistry. Pharmaceutical Research, 32, 3526-3540. [Google Scholar] [CrossRef] [PubMed]
[24] Sheyi, R., de la Torre, B.G. and Albericio, F. (2022) Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics, 14, Article No. 396. [Google Scholar] [CrossRef] [PubMed]
[25] Kovtun, Y.V., Audette, C.A., Ye, Y., Xie, H., Ruberti, M.F., Phinney, S.J., et al. (2006) Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen. Cancer Research, 66, 3214-3221. [Google Scholar] [CrossRef] [PubMed]
[26] Polson, A.G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., et al. (2009) Antibody-Drug Conjugates for the Treatment of Non-Hodgkin’s Lymphoma: Target and Linker-Drug Selection. Cancer Research, 69, 2358-2364. [Google Scholar] [CrossRef] [PubMed]
[27] McCombs, J.R. and Owen, S.C. (2015) Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry. The AAPS Journal, 17, 339-351. [Google Scholar] [CrossRef] [PubMed]
[28] Jenkins, D. (2007) Histopathology and Cytopathology of Cervical Cancer. Disease Markers, 23, 199-212. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, Y. (2024) The Effects of PIK3CA Mutations on Cervical Cancer. E3S Web of Conferences, 553, Article No. 05025. [Google Scholar] [CrossRef] 
[30] Pal, A. and Kundu, R. (2020) Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Frontiers in Microbiology, 10, Article No. 3116. [Google Scholar] [CrossRef] [PubMed]
[31] Knoff, J., Yang, B., Hung, C. and Wu, T. (2013) Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis. Current Obstetrics and Gynecology Reports, 3, 18-32. [Google Scholar] [CrossRef] [PubMed]
[32] Magnus, N., Garnier, D., Meehan, B., McGraw, S., Lee, T.H., Caron, M., et al. (2014) Tissue Factor Expression Provokes Escape from Tumor Dormancy and Leads to Genomic Alterations. Proceedings of the National Academy of Sciences, 111, 3544-3549. [Google Scholar] [CrossRef] [PubMed]
[33] Alley, S.C., Harris, J.R., Cao, A., Heuvel, E.G.d., Velayudhan, J., Satijn, D., et al. (2019) Abstract 221: Tisotumab Vedotin Induces Anti-Tumor Activity through MMAE-Mediated, Fc-Mediated, and Fab-Mediated Effector Functions in Vitro. Cancer Research, 79, 221-221. [Google Scholar] [CrossRef] 
[34] Zhao, X., Cheng, C., Gou, J., Yi, T., Qian, Y., Du, X., et al. (2018) Expression of Tissue Factor in Human Cervical Carcinoma Tissue. Experimental and Therapeutic Medicine, 16, 4075-4081. [Google Scholar] [CrossRef] [PubMed]
[35] Cocco, E., Varughese, J., Buza, N., Bellone, S., Glasgow, M., Bellone, M., et al. (2011) Expression of Tissue Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for Immunotherapy with Hi-Con1, a Factor VII-Iggfcchimeric Protein Targeting Tissue Factor. BMC Cancer, 11, Article No. 263. [Google Scholar] [CrossRef] [PubMed]
[36] Bogani, G., Coleman, R.L., Vergote, I., Raspagliesi, F., Lorusso, D. and Monk, B.J. (2023) Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer. Current Problems in Cancer, 47, Article ID: 100952. [Google Scholar] [CrossRef] [PubMed]
[37] Breij, E.C.W., de Goeij, B.E.C.G., Verploegen, S., Schuurhuis, D.H., Amirkhosravi, A., Francis, J., et al. (2014) An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. Cancer Research, 74, 1214-1226. [Google Scholar] [CrossRef] [PubMed]
[38] Tong, J.T.W., Harris, P.W.R., Brimble, M.A. and Kavianinia, I. (2021) An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules, 26, Article No. 5847. [Google Scholar] [CrossRef] [PubMed]
[39] Coleman, R.L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., et al. (2021) Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer (Innovatv 204/gog-3023/engot-Cx6): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 22, 609-619. [Google Scholar] [CrossRef] [PubMed]
[40] Vergote, I.B., Monk, B.J., O’Cearbhaill, R.E., Westermann, A.M., Banerjee, S., Collins, D.C., et al. (2021) 723MO Tisotumab Vedotin (TV) + Carboplatin (Carbo) in First-Line (1L) or + Pembrolizumab (Pembro) in Previously Treated (2L/3L) Recurrent or Metastatic Cervical Cancer (r/mcc): Interim Results of Engot-Cx8/gog-3024/innovatv 205 Study. Annals of Oncology, 32, S726-S727. [Google Scholar] [CrossRef] 
[41] Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., et al. (2024) Tisotumab Vedotin as Second-or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine, 391, 44-55. [Google Scholar] [CrossRef] [PubMed]
[42] Heitz, N., Greer, S.C. and Halford, Z. (2022) A Review of Tisotumab Vedotin-TFTV in Recurrent or Metastatic Cervical Cancer. Annals of Pharmacotherapy, 57, 585-596. [Google Scholar] [CrossRef] [PubMed]
[43] Citri, A. and Yarden, Y. (2006) EGF-ERBB Signalling: Towards the Systems Level. Nature Reviews Molecular Cell Biology, 7, 505-516. [Google Scholar] [CrossRef] [PubMed]
[44] Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D.E., Kelbick, N., Copeland, L., et al. (2006) HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association with Outcome in a Large Cohort of Surgically Staged Patients. Journal of Clinical Oncology, 24, 2376-2385. [Google Scholar] [CrossRef] [PubMed]
[45] Luo, H., Xu, X., Ye, M., Sheng, B. and Zhu, X. (2018) The Prognostic Value of HER2 in Ovarian Cancer: A Meta-Analysis of Observational Studies. PLOS ONE, 13, e0191972. [Google Scholar] [CrossRef] [PubMed]
[46] Diver, E.J., Foster, R., Rueda, B.R. and Growdon, W.B. (2015) The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. The Oncologist, 20, 1058-1068. [Google Scholar] [CrossRef] [PubMed]
[47] Tuefferd, M., Couturier, J., Penault-Llorca, F., Vincent-Salomon, A., Broët, P., Guastalla, J., et al. (2007) HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. PLOS ONE, 2, e1138. [Google Scholar] [CrossRef] [PubMed]
[48] 齐丽敏, 孙波, 张学玲, 等. hTERC、HER-2和c-myc基因在宫颈异常细胞中的表达及意义[J]. 实用医学杂志, 2015(18): 3021-3023.
[49] Chavez-Blanco, A., Perez-Sanchez, V., Gonzalez-Fierro, A., Vela-Chavez, T., Candelaria, M., Cetina, L., et al. (2004) HER2 Expression in Cervical Cancer as a Potential Therapeutic Target. BMC Cancer, 4, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
[50] Fortman, D., Issa, R., Stanbery, L., Albrethsen, M., Nemunaitis, J. and Kasunic, T. (2020) Her2-Positive Metastatic Cervical Cancer Responsive to First and Second-Line Treatment: A Case Report. Gynecologic Oncology Reports, 31, Article ID: 100520. [Google Scholar] [CrossRef] [PubMed]
[51] Nakada, T., Sugihara, K., Jikoh, T., Abe, Y. and Agatsuma, T. (2019) The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (ds-8201a), for HER2 Cancer Therapy. Chemical and Pharmaceutical Bulletin, 67, 173-185. [Google Scholar] [CrossRef] [PubMed]
[52] Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., et al. (2022) Trastuzumab Deruxtecan in Previously Treated Her2-Low Advanced Breast Cancer. New England Journal of Medicine, 387, 9-20. [Google Scholar] [CrossRef] [PubMed]
[53] Andrikopoulou, A., Zografos, E., Liontos, M., Koutsoukos, K., Dimopoulos, M. and Zagouri, F. (2021) Trastuzumab Deruxtecan (ds-8201a): The Latest Research and Advances in Breast Cancer. Clinical Breast Cancer, 21, e212-e219. [Google Scholar] [CrossRef] [PubMed]
[54] Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., et al. (2016) Ds-8201a, a Novel Her2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-dm1. Clinical Cancer Research, 22, 5097-5108. [Google Scholar] [CrossRef] [PubMed]
[55] Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. and Agatsuma, T. (2016) Bystander Killing Effect of ds‐8201a, a Novel Anti‐human Epidermal Growth Factor Receptor 2 Antibody-Drug Conjugate, in Tumors with Human Epidermal Growth Factor Receptor 2 Heterogeneity. Cancer Science, 107, 1039-1046. [Google Scholar] [CrossRef] [PubMed]
[56] Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., et al. (2019) [fam‐] Trastuzumab Deruxtecan, Antitumor Activity Is Dependent on HER2 Expression Level Rather than on her2 Amplification. International Journal of Cancer, 145, 3414-3424. [Google Scholar] [CrossRef] [PubMed]
[57] Tsurutani, J., Iwata, H., Krop, I., Jänne, P.A., Doi, T., Takahashi, S., et al. (2020) Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery, 10, 688-701. [Google Scholar] [CrossRef] [PubMed]
[58] Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S., González-Martín, A., et al. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Her2-Expressing Solid Tumors: Primary Results from the Destiny-Pantumor02 Phase II Trial. Journal of Clinical Oncology, 42, 47-58. [Google Scholar] [CrossRef] [PubMed]
[59] Mosele, M.F., Lusque, A., Dieras, V., Deluche, E., Ducoulombier, A., Pistilli, B., et al. (2022) LBA1 Unraveling the Mechanism of Action and Resistance to Trastuzumab Deruxtecan (t-Dxd): Biomarker Analyses from Patients from DAISY Trial. Annals of Oncology, 33, S123. [Google Scholar] [CrossRef] 
[60] Yu, J., Fang, T., Yun, C., Liu, X. and Cai, X. (2022) Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Frontiers in Molecular Biosciences, 9, Article ID: 847835. [Google Scholar] [CrossRef] [PubMed]
[61] Hu, X., Zhang, J., Liu, R., Gao, S., Wu, J., Wang, Y., et al. (2022) Updated Results and Biomarker Analyses from the Phase I Trial of A166 in Patients with Her2-Expressing Locally Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology, 40, 1037-1037. [Google Scholar] [CrossRef] 
[62] Li, H., Yu, C., Jiang, J., Huang, C., Yao, X., Xu, Q., et al. (2016) An Anti-Her2 Antibody Conjugated with Monomethyl Auristatin E Is Highly Effective in Her2-Positive Human Gastric Cancer. Cancer Biology & Therapy, 17, 346-354. [Google Scholar] [CrossRef] [PubMed]
[63] Xu, Y., Wang, Y., Gong, J., Zhang, X., Peng, Z., Sheng, X., et al. (2021) Phase I Study of the Recombinant Humanized Anti-Her2 Monoclonal Antibody-mmae Conjugate RC48-ADC in Patients with Her2-Positive Advanced Solid Tumors. Gastric Cancer, 24, 913-925. [Google Scholar] [CrossRef] [PubMed]
[64] Zaman, S., Jadid, H., Denson, A.C. and Gray, J.E. (2019) Targeting Trop-2 in Solid Tumors: Future Prospects. OncoTargets and Therapy, 12, 1781-1790. [Google Scholar] [CrossRef] [PubMed]
[65] Starodub, A.N., Ocean, A.J., Shah, M.A., Guarino, M.J., Picozzi, V.J., Vahdat, L.T., et al. (2015) First-in-Human Trial of a Novel Anti-Trop-2 Antibody-Sn-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical Cancer Research, 21, 3870-3878. [Google Scholar] [CrossRef] [PubMed]
[66] Syed, Y.Y. (2020) Sacituzumab Govitecan: First Approval. Drugs, 80, 1019-1025. [Google Scholar] [CrossRef] [PubMed]
[67] Zhai, C., Cui, Y., Guo, L., Chen, C., Song, Y., Zhong, J., et al. (2024) Progress in the Study of Antibody-Drug Conjugates for the Treatment of Cervical Cancer. Frontiers in Oncology, 14, Article ID: 1395784. [Google Scholar] [CrossRef] [PubMed]
[68] Samanta, D. and Almo, S.C. (2014) Nectin Family of Cell-Adhesion Molecules: Structural and Molecular Aspects of Function and Specificity. Cellular and Molecular Life Sciences, 72, 645-658. [Google Scholar] [CrossRef] [PubMed]
[69] Bouleftour, W., Guillot, A. and Magne, N. (2022) The Anti-Nectin 4: A Promising Tumor Cells Target. a Systematic Review. Molecular Cancer Therapeutics, 21, 493-501. [Google Scholar] [CrossRef] [PubMed]
[70] Zhang, J., Liu, R., Gao, S., Li, X., Chen, J., Yao, X., et al. (2023) 659MO Preliminary Results from a Phase I/II Study of 9MW2821, an Antibody-Drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors. Annals of Oncology, 34, S464. [Google Scholar] [CrossRef] 
[71] Yan, P., Dong, Y., Zhang, F., Zhen, T., Liang, J., Shi, H., et al. (2024) Claudin18.2 Expression and Its Clinicopathological Feature in Adenocarcinoma from Various Parts. Journal of Clinical Pathology. [Google Scholar] [CrossRef] [PubMed]
[72] Lund, M.E., Campbell, D.H. and Walsh, B.J. (2020) The Role of Glypican-1 in the Tumour Microenvironment. In: Advances in Experimental Medicine and Biology, Springer International Publishing, 163-176. [Google Scholar] [CrossRef] [PubMed]
[73] Harada, E., Serada, S., Fujimoto, M., Takahashi, Y., Takahashi, T., Hara, H., et al. (2017) Glypican-1 Targeted Antibody-Based Therapy Induces Preclinical Antitumor Activity against Esophageal Squamous Cell Carcinoma. Oncotarget, 8, 24741-24752. [Google Scholar] [CrossRef] [PubMed]
[74] Matsuda, K., Maruyama, H., Guo, F., et al. (2001) Glypican-1 Is Overexpressed in Human Breast Cancer and Modulates the Mitogenic Effects of Multiple Heparin-Binding Growth Factors in Breast Cancer Cells. Cancer Research, 61, 5562-5569.
[75] Qiao, D., Meyer, K., Mundhenke, C., Drew, S.A. and Friedl, A. (2003) Heparan Sulfate Proteoglycans as Regulators of Fibroblast Growth Factor-2 Signaling in Brain Endothelial Cells. Journal of Biological Chemistry, 278, 16045-16053. [Google Scholar] [CrossRef] [PubMed]
[76] Kleeff, J., Ishiwata, T., Kumbasar, A., Friess, H., Büchler, M.W., Lander, A.D., et al. (1998) The Cell-Surface Heparan Sulfate Proteoglycan Glypican-1 Regulates Growth Factor Action in Pancreatic Carcinoma Cells and Is Overexpressed in Human Pancreatic Cancer. Journal of Clinical Investigation, 102, 1662-1673. [Google Scholar] [CrossRef] [PubMed]
[77] Meng, Y., Chu, T., Lin, S., Wu, P., Zhi, W., Peng, T., et al. (2021) Clinicopathological Characteristics and Prognosis of Cervical Cancer with Different Histological Types: A Population-Based Cohort Study. Gynecologic Oncology, 163, 545-551. [Google Scholar] [CrossRef] [PubMed]
[78] Matsuzaki, S., Serada, S., Hiramatsu, K., Nojima, S., Matsuzaki, S., Ueda, Y., et al. (2017) Anti‐Glypican‐1 Antibody‐drug Conjugate Exhibits Potent Preclinical Antitumor Activity against Glypican‐1 Positive Uterine Cervical Cancer. International Journal of Cancer, 142, 1056-1066. [Google Scholar] [CrossRef] [PubMed]
[79] García-Alonso, S., Ocaña, A. and Pandiella, A. (2018) Resistance to Antibody-Drug Conjugates. Cancer Research, 78, 2159-2165. [Google Scholar] [CrossRef] [PubMed]
[80] Loganzo, F., Sung, M. and Gerber, H. (2016) Mechanisms of Resistance to Antibody-Drug Conjugates. Molecular Cancer Therapeutics, 15, 2825-2834. [Google Scholar] [CrossRef] [PubMed]
[81] Collins, D., Bossenmaier, B., Kollmorgen, G. and Niederfellner, G. (2019) Acquired Resistance to Antibody-Drug Conjugates. Cancers, 11, Article No. 394. [Google Scholar] [CrossRef] [PubMed]
[82] Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., et al. (2023) Mechanisms of Resistance to Antibody-Drug Conjugates. International Journal of Molecular Sciences, 24, Article No. 9674. [Google Scholar] [CrossRef] [PubMed]
[83] Chen, Y., Xu, Y., Shao, Z. and Yu, K. (2022) Resistance to Antibody‐Drug Conjugates in Breast Cancer: Mechanisms and Solutions. Cancer Communications, 43, 297-337. [Google Scholar] [CrossRef] [PubMed]
[84] Kim, E.G. and Kim, K.M. (2015) Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomolecules & Therapeutics, 23, 493-509. [Google Scholar] [CrossRef] [PubMed]
[85] Dal Corso, A., Gébleux, R., Murer, P., Soltermann, A. and Neri, D. (2017) A Non-Internalizing Antibody-Drug Conjugate Based on an Anthracycline Payload Displays Potent Therapeutic Activity in Vivo. Journal of Controlled Release, 264, 211-218. [Google Scholar] [CrossRef] [PubMed]
[86] Liu, R., Wang, R.E. and Wang, F. (2016) Antibody-Drug Conjugates for Non-Oncological Indications. Expert Opinion on Biological Therapy, 16, 591-593. [Google Scholar] [CrossRef] [PubMed]
[87] Chu, Y. and Polson, A. (2013) Antibody-Drug Conjugates for the Treatment of B-Cell Non-Hodgkin’s Lymphoma and Leukemia. Future Oncology, 9, 355-368. [Google Scholar] [CrossRef] [PubMed]